<DOC>
	<DOCNO>NCT00870870</DOCNO>
	<brief_summary>The purpose study determine number participant whose cancer shrink disappears treatment study .</brief_summary>
	<brief_title>A Study IMC-A12 ( Cixutumumab ) With Without Other Standard Chemotherapies Patients With Lung Cancer Who Have Not Received Chemotherapy Before</brief_title>
	<detailed_description>Participants Stage IIIb IV NSCLC receive previous chemotherapy stratify , base disease histology ( squamous versus [ vs. ] nonsquamous ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Has histologically cytologically confirm , Stage IIIb IV NSCLC Has metastatic disease Has tumor measurable accord Response Evaluation Criteria Solid Tumors ( RECIST ) Has adequate hematologic function Has adequate hepatic function Has adequate renal function Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Has uncontrolled brain metastasis Has leptomeningeal disease Has receive previous chemotherapy NSCLC ( patient receive adjuvant chemotherapy eligible last administration prior adjuvant regimen occur least 6 month prior randomization ) Receiving investigational agent ( ) Has history treatment agent target IGF EGF receptor Has know allergy / history hypersensitivity reaction treatment component Has poorly control diabetes mellitus . Patients history diabetes mellitus allow participate , provide blood glucose within normal range ( fast glucose &lt; 160 mg/dL ULN hemoglobin A1C ≤ 7 % ) stable dietary therapeutic regimen condition Has uncontrolled intercurrent illness Pregnant lactating Has history another primary cancer , exception : ) curatively resect nonmelanomatous skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor treat curative intent know active disease present treatment administer last 3 year Has superior vena cava syndrome contraindicating hydration Has current clinicallyrelevant coronary artery disease ( New York Heart Association III IV ) uncontrolled congestive heart failure Has NCICTCAE Version 3.0 Grade ≥ 2 peripheral neuropathy Has significant third space fluid retention , require repeat drainage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Stage IIIb Metastatic Non-Small Cell Lung Cancer</keyword>
	<keyword>Stage IV Metastatic Non-Small Cell Lung Cancer</keyword>
</DOC>